Pharmacotherapeutic group: venopharmaceutical, antivaricose agent
ATC code: C05BX01
Calcium dobesilate acts on capillary walls by correcting their impaired physiological functions — increased permeability and decreased resistance. It increases erythrocyte flexibility, inhibits platelet aggregation, and in diabetic retinopathy reduces plasma and blood viscosity with subsequent improvement of blood rheological properties and tissue perfusion. These properties help correct capillary dysfunction, both functional and that caused by congenital or acquired metabolic disorders. Calcium dobesilate also helps reduce oedema.
⚠️ Warnings
In cases of severe renal insufficiency requiring dialysis, dose reduction may be considered.
In very rare cases, administration of calcium dobesilate may cause agranulocytosis (see section 4.8).
In such cases, symptoms such as high fever, oral cavity infections (tonsillitis), sore throat, anogenital inflammation, and other symptoms that are common signs of infection may occur. If any of these symptoms occur, treatment must be discontinued. An immediate blood count and leukocyte differential count must then be performed.
Doxium 500 may induce severe hypersensitivity reactions (anaphylactic reaction or shock). In the event of hypersensitivity reactions, treatment must be discontinued.
Elderly patients
In clinical studies with calcium dobesilate, the elderly population was well represented and no overall safety concerns were identified.
Paediatric population
No studies investigating the use of calcium dobesilate in the paediatric population have been conducted.
PillsCard reference image